Publications

Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales.

FLASCHE, S; Slack, M; Miller, E;

2011

EUROSURVEILLANCE, (2011).16 20(20), Art.No. ARTN 19868, 13-18.

Incremental costs of introducing jet injection technology for delivery of routine childhood vaccinations: comparative analysis from Brazil, India, and South Africa.

GRIFFITHS, UK; SANTOS, AC; Nundy, N; Jacoby, E; Matthias, D;

2011

Vaccine, (2011).29 5 10.1016/j.vaccine.2010.11.038.

Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.

Vekemans, J; Marsh, K; GREENWOOD, B; Leach, A; Kabore, W; Soulanoudjingar, S; ASANTE, KP; Ansong, D; Evans, J; Sacarlal, J; Bejon, P; Kamthunzi, P; Salim, N; Njuguna, P; Hamel, MJ; Otieno, W; Gesase, S; SCHELLENBERG, D; Clinical Trials Partnership Committee,;

2011

Malaria journal, (2011).10 1 10.1186/1475-2875-10-221.

Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales.

FLASCHE, S; Slack, M; MILLER, E;

2011

Euro surveillance, (2011).16 20

Long-term outcomes of pneumococcal meningitis in childhood and adolescence.

Christie, D; Viner, RM; Knox, K; Coen, PG; Wang, H; El Bashir, H; LEGOOD, R; Patel, BC; Booy, R;

2011

European journal of pediatrics, (2011).170 8 10.1007/s00431-010-1390-5.

A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.

Bélard, S; Issifou, S; Hounkpatin, AB; Schaumburg, F; Ngoa, UA; Esen, M; Fendel, R; De Salazar, PM; Mürbeth, RE; MILLIGAN, P; Imbault, N; Imoukhuede, EB; Theisen, M; Jepsen, S; Noor, RA; Okech, B; Kremsner, PG; Mordmüller, B;

2011

PloS one, (2011).6 7 10.1371/journal.pone.0022525.

Performance of the BioPlex 2200 multiplexing immunoassay platform for the detection of herpes simplex virus type 2 specific antibodies in African settings.

LeGoff, J; Grésenguet, G; Gody, C; Longo, JD D; Khonde, N; WEISS, HA; MAYAUD, P; Bélec, L; ANRS 12-12 Study Group,;

2011

Clinical and vaccine immunology, (2011).18 7 10.1128/CVI.05003-11.

Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.

Russell, FM; Carapetis, JR; Burton, RL; Lin, J; Licciardi, PV; Balloch, A; Tikoduadua, L; Waqatakirewa, L; Cheung, YB; Tang, ML K; Nahm, MH; MULHOLLAND, EK;

2011

Vaccine, (2011).29 3 10.1016/j.vaccine.2010.10.046.

A call to action for the new decade of vaccines.

Moxon, ER; Das, P; GREENWOOD, B; HEYMANN, DL; Horton, R; Levine, OS; Plotkin, S; Nossal, G;

2011

Lancet, (2011).378 9788 10.1016/S0140-6736(11)60766-6.

Human saliva as a source of anti-malarial antibodies to examine population exposure to Plasmodium falciparum.

Estévez, PT; Satoguina, J; NWAKANMA, DC; West, S; CONWAY, DJ; DRAKELEY, CJ;

2011

Malaria journal, (2011).10 1 10.1186/1475-2875-10-104.